Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort.

Fairclough SR, Kiedrowski LA, Lin JJ, Zelichov O, Tarcic G, Stinchcombe TE, Odegaard JI, Lanman RB, Shaw AT, Nagy RJ.

Exp Hematol Oncol. 2019 Oct 11;8:24. doi: 10.1186/s40164-019-0148-7. eCollection 2019.

2.

CRISPR-Directed Gene Editing Catalyzes Precise Gene Segment Replacement In Vitro Enabling a Novel Method for Multiplex Site-Directed Mutagenesis.

Sansbury BM, Wagner AM, Tarcic G, Barth S, Nitzan E, Goldfus R, Vidne M, Kmiec EB.

CRISPR J. 2019 Apr;2:121-132. doi: 10.1089/crispr.2018.0054.

PMID:
30998096
3.

CRISPR-Directed In Vitro Gene Editing of Plasmid DNA Catalyzed by Cpf1 (Cas12a) Nuclease and a Mammalian Cell-Free Extract.

Sansbury BM, Wagner AM, Nitzan E, Tarcic G, Kmiec EB.

CRISPR J. 2018 Apr 1;1(2):191-202. doi: 10.1089/crispr.2018.0006.

4.

Revisited analysis of a SHIVA01 trial cohort using functional mutational analyses successfully predicted treatment outcome.

Kamal M, Tarcic G, Dureau S, Edelheit O, Barbash Z, Lecerf C, Morel C, Miron B, Callens C, Servant N, Bieche I, Vidne M, Le Tourneau C.

Mol Oncol. 2018 May;12(5):594-601. doi: 10.1002/1878-0261.12180. Epub 2018 Mar 30.

5.

SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors.

Roth L, Srivastava S, Lindzen M, Sas-Chen A, Sheffer M, Lauriola M, Enuka Y, Noronha A, Mancini M, Lavi S, Tarcic G, Pines G, Nevo N, Heyman O, Ziv T, Rueda OM, Gnocchi D, Pikarsky E, Admon A, Caldas C, Yarden Y.

Sci Signal. 2018 Jan 30;11(515). pii: eaan0949. doi: 10.1126/scisignal.aan0949.

PMID:
29382783
6.

Corrigendum: The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.

Shema E, Tirosh I, Aylon Y, Huang J, Ye C, Moskovits N, Raver-Shapira N, Minsky N, Pirngruber J, Tarcic G, Hublarova P, Moyal L, Gana-Weisz M, Shiloh Y, Yarden Y, Johnsen SA, Vojtesek B, Berger SL, Oren M.

Genes Dev. 2017 Sep 15;31(18):1926. doi: 10.1101/gad.307207.117. No abstract available.

7.

Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer.

Peled N, Roisman LC, Miron B, Pfeffer R, Lanman RB, Ilouze M, Dvir A, Soussan-Gutman L, Barlesi F, Tarcic G, Edelheit O, Gandara D, Elkabetz Y.

J Thorac Oncol. 2017 Jul;12(7):e81-e84. doi: 10.1016/j.jtho.2017.02.023. Epub 2017 Mar 7. No abstract available.

8.

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.

Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S.

Cancer Discov. 2016 Dec;6(12):1352-1365. Epub 2016 Oct 11.

9.

Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression.

Cohen-Dvashi H, Ben-Chetrit N, Russell R, Carvalho S, Lauriola M, Nisani S, Mancini M, Nataraj N, Kedmi M, Roth L, Köstler W, Zeisel A, Yitzhaky A, Zylberg J, Tarcic G, Eilam R, Wigelman Y, Will R, Lavi S, Porat Z, Wiemann S, Ricardo S, Schmitt F, Caldas C, Yarden Y.

EMBO Mol Med. 2015 Mar;7(3):299-314. doi: 10.15252/emmm.201404134.

10.

ERK-ERF-EGR1, a novel switch underlying acquisition of a motile phenotype.

Ben-Chetrit N, Tarcic G, Yarden Y.

Cell Adh Migr. 2013 Jan-Feb;7(1):33-7. doi: 10.4161/cam.22263. Epub 2012 Oct 17.

11.

EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF.

Tarcic G, Avraham R, Pines G, Amit I, Shay T, Lu Y, Zwang Y, Katz M, Ben-Chetrit N, Jacob-Hirsch J, Virgilio L, Rechavi G, Mavrothalassitis G, Mills GB, Domany E, Yarden Y.

FASEB J. 2012 Apr;26(4):1582-92. doi: 10.1096/fj.11-194654. Epub 2011 Dec 23.

12.

MAP Kinase activation by receptor tyrosine kinases: in control of cell migration.

Tarcic G, Yarden Y.

Methods Mol Biol. 2010;661:125-35. doi: 10.1007/978-1-60761-795-2_7.

PMID:
20811980
13.

EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors.

Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalgi R, Tarcic G, Bossel N, Zeisel A, Amit I, Zwang Y, Enerly E, Russnes HG, Biagioni F, Mottolese M, Strano S, Blandino G, Børresen-Dale AL, Pilpel Y, Yakhini Z, Segal E, Yarden Y.

Sci Signal. 2010 Jun 1;3(124):ra43. doi: 10.1126/scisignal.2000876.

14.

An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis.

Tarcic G, Boguslavsky SK, Wakim J, Kiuchi T, Liu A, Reinitz F, Nathanson D, Takahashi T, Mischel PS, Ng T, Yarden Y.

Curr Biol. 2009 Nov 17;19(21):1788-98. doi: 10.1016/j.cub.2009.09.048.

15.

The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.

Shema E, Tirosh I, Aylon Y, Huang J, Ye C, Moskovits N, Raver-Shapira N, Minsky N, Pirngruber J, Tarcic G, Hublarova P, Moyal L, Gana-Weisz M, Shiloh Y, Yarden Y, Johnsen SA, Vojtesek B, Berger SL, Oren M.

Genes Dev. 2008 Oct 1;22(19):2664-76. doi: 10.1101/gad.1703008. Erratum in: Genes Dev. 2017 Sep 15;31(18):1926.

16.

A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration.

Katz M, Amit I, Citri A, Shay T, Carvalho S, Lavi S, Milanezi F, Lyass L, Amariglio N, Jacob-Hirsch J, Ben-Chetrit N, Tarcic G, Lindzen M, Avraham R, Liao YC, Trusk P, Lyass A, Rechavi G, Spector NL, Lo SH, Schmitt F, Bacus SS, Yarden Y.

Nat Cell Biol. 2007 Aug;9(8):961-9. Epub 2007 Jul 22.

PMID:
17643115
17.

A module of negative feedback regulators defines growth factor signaling.

Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, Tarcic G, Siwak D, Lahad J, Jacob-Hirsch J, Amariglio N, Vaisman N, Segal E, Rechavi G, Alon U, Mills GB, Domany E, Yarden Y.

Nat Genet. 2007 Apr;39(4):503-12. Epub 2007 Feb 25.

PMID:
17322878
18.

MHC class I-independent recognition of NK-activating receptor KIR2DS4.

Katz G, Gazit R, Arnon TI, Gonen-Gross T, Tarcic G, Markel G, Gruda R, Achdout H, Drize O, Merims S, Mandelboim O.

J Immunol. 2004 Aug 1;173(3):1819-25.

Supplemental Content

Loading ...
Support Center